 |
|
|
 |
|
|
Sills Cummis & Gross Represented Optherion in $37 Million Financing
Newark, NJ -- 10/17/2007 Optherion, Inc., a company developing products to diagnose and treat dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced on October 9, 2007 that it has raised $37 million in start up financing. Sills Cummis & Gross attorneys Ira A. Rosenberg, Lori M. Waldron, Laurajane B. Kastner and James A. Dempsey represented Optherion in connection with this financing.
Optherion’s initial focus is to develop disease-modifying therapies to prevent loss of vision in patients with dry AMD, the leading cause of blindness in people over 60 in the developed world, as well as a portfolio of tests that predict, diagnose and monitor progression of the disease.
Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA, and GE Healthcare Financial Services, Chicago, IL.
For more information regarding this press release, you may contact Marcia Jeffers via email at
or directly at:
The Legal Center
One Riverfront Plaza
Newark, NJ 07102
(973) 643-4215
Sills Cummis & Gross P.C. is a full-service corporate law firm with over 175 attorneys in New Jersey and New York. The Firm’s work is diversified among industries such as pharmaceutical and medical device, banking and finance, retail and commercial real estate, health care, life sciences, manufacturing, technology and telecommunications.
|
|
|
| Related Attorneys |
|
| Rosenberg, Ira A. |
| Waldron, Lori M. |
| Kastner, Laurajane B. |
|
|
